Abstract
The novel Coronavirus SARS-CoV-2 is the viral pathogen responsible for the ongoing global pandemic, COVID-19 (Coronavirus disease 2019). To date, the data recorded indicate 1.62 Mln deaths and 72.8 Mln people infected (WHO situation report Dec 2020). On December 27, the first anti-COVID-19 vaccinations started in Europe. There are no direct antivirals against SARS-CoV-2. Understanding the pathophysiological and inflammatory/immunological processes of SARS-CoV-2 infection is essential to identify new drug therapies. In the most severe COVID-19 cases, an unregulated immunological/inflammatory system results in organ injury that can be fatal to the host in some cases. Pharmacologic approaches to normalize the unregulated inflammatory/immunologic response is an important therapeutic solution. Evidence associates a non-regulation of the “complement system” as one of the causes of generalized inflammation causing multi-organ dysfunction. Serum levels of a complement cascade mediator, factor “C5a”, have been found in high concentrations in the blood of COVID-19 patients with severe disease. In this article we discuss the correlation between complement system and COVID-19 infection and pharmacological solutions directed to regulate.
Keywords: COVID-19; Complement system; Eculizumab; Inflammatory/immunological; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, complement system, eculizumab, Inflammatory/immunological, 【초록키워드】 SARS-CoV-2, Inflammation, Coronavirus disease 2019, Europe, vaccination, severe COVID-19, Antiviral, multi-organ dysfunction, SARS-COV-2 infection, complement, global pandemic, COVID-19 infection, therapeutic, death, understanding, WHO, correlation, Blood, Therapies, Concentration, regulate, severe disease, COVID-19 patient, organ injury, cascade, viral pathogen, Pharmacologic, pharmacological, Host, approach, responsible, identify, cause, recorded, pathophysiological, 【제목키워드】 complement, Inflammatory, reduction, cascade, approach, prothrombotic, acting, COVID-19 positive patient,